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Introduction {#sec1}
============

The fly respiratory system (i.e., the trachea) is the equivalent of the mammalian lung with similarities in development and immunity, which make it a useful model for numerous human respiratory diseases ([@bib7]). The tracheal system consists of a network of air-filled epithelial tubes. These tubes contain a cuticular lining that provides structural support, through ridges known as taenidia. As the larva grows the trachea must also grow to match the increased oxygen demand of the tissue. During molting the old cuticular lining separates from the tracheal epithelium, and what is presumed to be molting fluid fills the space between the old and new lining. The old lining collapses and is removed from the trachea, followed immediately by filling of the trachea with air and removal of molting fluid ([@bib42]). However, little is known about the molecular mechanisms underlying larval tracheal air filling.

The trachea is open to the environment and thus vulnerable to infection. Tracheal epithelial cells have a number of innate defenses including the expression of antimicrobial peptides (AMPs) ([@bib59]; [@bib60]; [@bib7]) and melanization, an arthropod-specific response to wounds or infections ([@bib54]). The production of melanin is catalyzed by prophenoloxidases (PPOs), zymogens that are activated by serine protease cascades ([@bib53]; [@bib12]). Outside the trachea, melanization is typically mediated by specialized immune cells known as crystal cells, which can be triggered to release PPOs into the hemolymph ([@bib52]).

Mitochondria are extremely multifaceted organelles with roles in metabolism, apoptosis, cell signaling, and more. Reversible phosphorylation is one mechanism by which mitochondrial activities are regulated ([@bib38]). Protein-tyrosine-phosphatase localized to the mitochondrion 1 (PTPMT1) is a phosphatase that resides on the inner mitochondrial membrane, where it regulates mitochondrial functions through its phosphatase activity ([@bib40], [@bib39]). Studies from vertebrate systems have shown that PTPMT1 controls pyruvate importation and utilization in the mitochondria through regulation of phosphatidylinositol phosphate (PIP) levels, modulates crista structure and respiratory chain function through the synthesis of cardiolipin (CL)---the hallmark phospholipid of the mitochondria ([@bib68]; [@bib63]; [@bib55]), and regulates the tricarboxylic acid (TCA) cycle through succinate dehydrogenase ([@bib32]). Loss of *PTPMT1* in a variety of mammalian cell types results in decreased mitochondrial respiration and increased glycolysis. These metabolic changes have drastic impacts on stem cells and cancer cells, but not on other cell types, demonstrating that the functional consequences of PTPMT1 depletion are highly cell-type-specific ([@bib39]; [@bib49]; [@bib68]; [@bib33]; [@bib66]; [@bib69]). Although PTPMT1 is broadly expressed and highly conserved among species ([@bib40], [@bib39]; [@bib49]; [@bib55]), to date, it has only been examined in a narrow number of tissues and cell types and predominately in vertebrates, limiting our understanding of PTPMT1\'s distinct cell-type-specific roles *in vivo*. *Drosophila melanogaster* is an unparalleled genetic model for studying tracheal biology and gene function, with methods for the rapid generation of mutants as well as expansive collections of existing mutants and RNA interference (RNAi) lines. Here, we examine the physiological functions of *PTPMT1* in *Drosophila* and report a role for PTPMT1 in fly tracheal epithelial cells.

Results {#sec2}
=======

*dPTPMT1* Is an Essential Gene in *Drosophila* {#sec2.1}
----------------------------------------------

To study the function of *Drosophila* PTPMT1 (dPTPMT1), we employed CRISPR-CAS9 to create a defined deletion in *dPTPMT1* that would remove most of its coding sequence ([@bib16], [@bib17]) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). We failed to isolate the intended deletion but were able to obtain three independent lines with small deletions in the regions targeted by our gRNAs: *dPTPMT1*^*mut1*^ (c.487delA), *dPTPMT1*^*mut2*^ (c.479_489delCGGATGGACTC), and *dPTPMT1*^*mut3*^ (c.12 + 82delT and c487delA) ([Figures 1](#fig1){ref-type="fig"}A, [S1](#mmc1){ref-type="supplementary-material"}B, and S1C). All three lines were homozygous lethal and also lethal over two deficiency lines covering *dPTPMT1* (*Df(3R)BSC490* and *Df(3R)Exel9013*). The failure to complement indicates that lethality is likely caused by mutations in *dPTPMT1*. In all lines, both as homozygotes and transheterozygotes (over *Df(3R)BSC490*), third instar larvae were present, albeit at reduced frequencies, likely due to the increased early lethality ([Figure 1](#fig1){ref-type="fig"}B). None of these larval escapers were able to undergo pupariation and survive to adulthood ([Figure 1](#fig1){ref-type="fig"}C). We collected age-synchronized embryos (3 h after egg laying--AEL) and examined viability 24 h AEL. We found approximately 80% of first instar larvae of *dPTPMT1*^*mut1*^ that hatched died soon after ([Figure 1](#fig1){ref-type="fig"}B). The lethality rates were comparable between *dPTPMT1*^*mut1*^ homozygotes and transheterozygotes. These results suggest that *dPTPMT1*^*mut1*^represents a null allele or strong hypomorph.Figure 1*dPTPMT1* Is an Essential Gene in *Drosophila*(A) Regions in *dPTPMT1* targeted by the three RNAi lines. Thin black bars indicate regions targeted by RNAi, dark gray bar is the 5′ UTR, light gray bar is the 3′ UTR, purple bars are exons, and thick black bars are introns. Asterisk indicates the location of the deletion in *dPTPMT1*^*mut1*^.(B) Viability of *dPTPMT1*^*mut1*^ first instar larvae at 24 h AEL. n = 4--5 replicates, 56--285 for each repeat. Data are represented as mean ± SEM and ∗∗∗p \< 0.001 by chi-square test.(C) Adult viability of *dPTPMT1*^*mut1*^ mutants. Genotypic frequency is calculated for adults and then normalized to expected genotypic frequency. n = 3--4 replicates; 0- to 2-day-old adults. Data are represented as mean ± SEM and ∗∗∗p \< 0.001 by chi-square test.(D) Percentage of third instar males with ubiquitous *dPTPMT1* RNAi surviving to pupation and eclosion. Larvae are on a yellow mutant background (hereafter indicated by "*y"*). Statistical significance is given relative to *Act5C-GAL4* crossed to the respective RNAi background controls at the same developmental stage. n = 3 replicates, 25--26 for each repeat for RNAi 1-2 and controls. n = 3 replicates, 12--44 for each repeat for RNAi 3 and control.Data are represented as mean ± SEM and ∗∗p \< 0.01, ∗∗∗p \< 0.001 by chi-square test. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To complement the CRISPR mutants, we obtained three *UAS-dPTPMT1* RNAi lines from the Vienna *Drosophila* RNAi Center and the *Drosophila* Transgenic RNAi Project collections ([@bib9]; [@bib43]). All three *UAS-dPTPMT1* RNAi insertions are at independent genomic locations. RNAi 1 and 2 target the same region within the third exon of *dPTPMT1*, whereas RNAi 3 targets the fourth exon of *dPTPMT1*, allowing us to control for off-target effects ([Figure 1](#fig1){ref-type="fig"}A). Ubiquitous *dPTPMT1* RNAi with the driver *Act5C-GAL4* reduced *dPTPMT1* transcripts to below 20% of wild-type levels for all three lines, as detected by quantitative real-time PCR (qPCR) ([Figure S1](#mmc1){ref-type="supplementary-material"}D). *dPTPMT1* RNAi 1 and 3 were pupal lethal ([Figure 1](#fig1){ref-type="fig"}D). RNAi 2 allowed adult survivors but with a significant decrease in viability compared with wild-type controls ([Figure 1](#fig1){ref-type="fig"}D). Given the conservation in protein sequence between PTPMT1 and PTEN\'s catalytic regions ([@bib40]), we also verified that *dPTPMT1* RNAi did not affect fly *PTEN* (*dPten*) transcript levels by qPCR ([Figure S1](#mmc1){ref-type="supplementary-material"}E).

To study the structure-function relationship of dPTPMT1 *in vivo*, we generated *UAS-dPTPMT1* transgenic fly lines, including wild-type (WT) *dPTPMT1*, catalytic-dead (CD; with a C141S mutation) *dPTPMT1*, and *dPTPMT1* with a deletion of its putative mitochondrial targeting sequence (ΔMTS; removing amino acids 1--31) ([@bib39]). All transgenes were inserted into the same genomic region using the PhiC31 integrase-mediated transgenesis system ([@bib29]). To test the functional conservation of PTPMT1 between flies and humans, we also generated *UAS-human PTPMT1 (hPTPMT1)* and *UAS-hPTPMT1-CD* (C132S) ([@bib68]). Because we were unable to generate an antibody or identify a commercially available antibody that recognized dPTPMT1, we tagged all transgenes with *3×FLAG*. We confirmed that the expression of these transgenes driven by *Act5C-GAL4* were comparable using immunoblotting against FLAG ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G).

To examine the localization of exogenously expressed dPTPMT1, we performed mitochondrial enrichments using adults or larvae with ubiquitous expression of each of our transgenes. We used the inner mitochondrial membrane protein, dMIC60, as a positive control for enrichment of mitochondria ([@bib57]). Exogenously expressed dPTPMT1-WT-3×FLAG was detected in the mitochondrial-enriched fraction, although it was also detected in the cytosolic fraction ([Figure S1](#mmc1){ref-type="supplementary-material"}H). Deletion of the putative MTS decreased dPTPMT1-3×FLAG levels in the mitochondrial-enriched fraction ([Figure S1](#mmc1){ref-type="supplementary-material"}I), suggesting that the N-terminal amino acids 1--31 direct dPTPMT1 import into mitochondria. These results are consistent with a previous study in yeast showing that heterologously expressed dPTPMT1 localizes to mitochondria ([@bib55]). Importantly, dPTPMT1-CD-3×FLAG was also detected in the mitochondrial fraction ([Figure S1](#mmc1){ref-type="supplementary-material"}J). We next assayed flies with ubiquitous expression of *UAS-hPTPMT1-WT-3*×*FLAG* and *UAS-hPTPMT1-CD-3*×*FLAG* and detected both versions of hPTPMT1 in the mitochondrial fraction ([Figure S1](#mmc1){ref-type="supplementary-material"}K). Collectively, the generation of these transgenes allowed us to perform the following functional studies of PTPMT1 in flies.

To corroborate that the lethality observed in *dPTPMT1* CRISPR mutants was caused by a lack of dPTPMT1, we ubiquitously expressed *UAS-dPTPMT1*-*3*×*FLAG* in *dPTPMT1*^*mut1*^ transheterozygotes. Ubiquitous expression of *UAS-dPTPMT1-3*×*FLAG* allowed mutants to survive to adulthood, eclosing at the expected genotypic ratio ([Figure 1](#fig1){ref-type="fig"}C). This result confirms that the lethality of *dPTPMT1* CRISPR mutants is caused by the loss of dPTPMT1. It should be noted that we were unable to quantify viability in this rescue experiment by counting the numbers of survivors of larvae and pupae as implemented in [Figure 1](#fig1){ref-type="fig"}D, because one of the lines necessary for the identification of genotypes of third instars could not be generated. Instead, we quantified viability by calculating the genotypic ratio of surviving adults and then normalizing it to the expected genotypic frequency. Importantly, expression of *ΔMTS-dPTPMT1-3*×*FLAG* and *dPTPMT1-CD-3*×*FLAG* failed to rescue viability of CRISPR mutants ([Figure 1](#fig1){ref-type="fig"}C), indicating that mitochondrial localization and catalytic activity are required for dPTPMT1\'s function. Ubiquitous expression of *UAS-hPTPMT1-WT-3*×*FLAG*, but not *UAS*-*hPTPMT1-CD-3*×*FLAG*, was also able to rescue viability ([Figure 1](#fig1){ref-type="fig"}C), indicating that human and fly PTPMT1 are functionally conserved. Notably, expression of *dPTPMT1* in specific tissues such as the trachea by *btl-GAL4*, neurons by *elav-GAL4*, or muscles by *Mhc-GAL4* did not rescue the viability of *dPTPMT1*^*mut1*^ transheterozygotes, indicating that dPTPMT1 is required in multiple tissues in *Drosophila* for survival. Collectively, these data suggest that *dPTPMT1* is essential for viability in the fly.

Depletion of dPTPMT1 Causes Tracheal Blackening {#sec2.2}
-----------------------------------------------

We noticed that ubiquitous *dPTPMT1* RNAi resulted in tracheal blackening in both adults and third instar larvae ([Figure 2](#fig2){ref-type="fig"}A). All three *dPTPMT1* RNAi lines showed a significantly higher frequency of tracheal blackening than controls ([Figures 2](#fig2){ref-type="fig"}B--2D). By contrast, ubiquitous *GFP* RNAi did not cause significant tracheal blackening, indicating that this phenotype is not an artifact of the RNAi system ([Figures 2](#fig2){ref-type="fig"}B and 2C). Using transmission electron microscopy (TEM) on a section of trachea from a third instar larva with ubiquitous *dPTPMT1* RNAi, we discovered large electron-dense regions between the tracheal cuticle and the tracheal epithelial cells ([Figure S2](#mmc1){ref-type="supplementary-material"}A). To test whether this tracheal blackening was due to melanization, we used RNAi to ubiquitously knockdown *MP1*, a serine protease reported to be involved in activating tracheal melanization ([@bib53], [@bib54]). Using qPCR, we confirmed a significant reduction of *MP1* transcripts ([Figure S2](#mmc1){ref-type="supplementary-material"}B). We saw a substantial decrease in the strength and frequency of tracheal blackening in *dPTPMT1* RNAi flies by *MP1* RNAi but not by *GFP* RNAi ([Figures 2](#fig2){ref-type="fig"}B and 2C). These results indicate that tracheal blackening is at least partially a result of melanization.Figure 2dPTPMT1 Depletion Results in Tracheal Blackening(A) Ubiquitous *dPTPMT1* RNAi results in tracheal blackening (arrows); 0- to 2-day-old adult males and third instar males are shown. Scale bars, 250 μm.(B and C) Percentage of 0- to 2-day-old adult males with tracheal blackening (B) and strength of tracheal blackening (C). n = 3 replicates, 48--138 for each repeat. Data are represented as mean ± SEM and ∗∗∗p \< 0.001 by chi-square test.(D) Percentage of third instars with tracheal blackening; mixed-sex, females are heterozygous for *y* and males are hemizygous for *y* (hereafter denoted as *y/y*^*+*^). n = 3 replicates, 25--43 for each repeat. Data are represented as mean ± SEM and ∗∗∗p \< 0.001 by chi-square test.(E) Viability of tracheal-specific *dPTPMT1* RNAi larvae. Statistical significance is given relative to *btl-GAL4* crossed to respective RNAi background controls at the same developmental stage. n = 2--3 replicates, 50--100 for each repeat. Data are represented as mean ± SEM and ∗∗∗p \< 0.001 by chi-square test.(F) Percentage of second instar, tracheal-specific *dPTPMT1* RNAi larvae with tracheal blackening. n = 2--3 replicates, 38--94 for each repeat. Data are represented as mean ± SEM and ∗∗∗p \< 0.001 by chi-square test.(G) A representative image of a second instar larva with tracheal-specific *dPTPMT1* RNAi shows tracheal blackening (arrow). Scale bars, 250 μm.(H) Tracheal blackening (arrows) in *dPTPMT1*^*mut1*^ third instar larvae. Scale bars, 250 μm.(I) Percentage of *dPTPMT1*^*mut1*^ third instars with tracheal blackening. n = 2--4 replicates, 16--110 for each repeat.Data are represented as mean ± SEM and ∗∗∗p \< 0.001 by chi-square test. See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

To determine whether this blackening phenotype was cell autonomous, we performed a tracheal-specific RNAi knockdown of *dPTPMT1*, using *btl-GAL4* ([@bib25]). Both *dPTPMT1* RNAi 1 and 3 resulted in early lethality ([Figure 2](#fig2){ref-type="fig"}E). We found that over half of *dPTPMT1* RNAi larvae were dead by 72 h AEL ([Figure 2](#fig2){ref-type="fig"}E). It should be noted that, in this particular experiment at 72 h AEL, the majority of larvae (control and RNAi) were second instars ([Figure S2](#mmc1){ref-type="supplementary-material"}C), due to the developmental delay caused by sorting first instars at room temperature (22°C) at hatching (see [Methods](#sec4){ref-type="sec"}). Many of these larvae were found dead on the side of the vial, suggesting that they died of anoxia as second instar larvae ([@bib60]). Importantly, first instar larvae with tracheal *dPTPMT1* RNAi showed no sign of tracheal blackening (*btl-GAL4*---Control for RNAi 1: 0% ± 0%*, btl-GAL4\>UAS-dPTPMT1* RNAi 1: 0% ± 0%; *btl-GAL4*---Control for RNAi 3: 0% ± 0%, *btl-GAL4\>UAS-dPTPMT1* RNAi 3: 1% ± 1%; n = 2--3 replicates, 37--97 for each repeat). However, nearly all second instar larvae had blackened trachea ([Figures 2](#fig2){ref-type="fig"}F and 2G). TEM on a section of trachea from a third instar escaper with tracheal-specific *dPTPMT1* RNAi also revealed large electron-dense regions between the tracheal cuticle and the tracheal epithelial cells ([Figure S2](#mmc1){ref-type="supplementary-material"}D), like ubiquitous *dPTPMT1* RNAi ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Therefore, tracheal blackening occurs during the transition from first to second instar in tracheal-specific *dPTPMT1* RNAi larvae.

Melanization can be activated by the trachea ([@bib54]). However, it can also be mediated by phenol oxidases, released by crystal cells, in the hemolymph ([@bib52]). Knockdown of *MP1* specifically in the trachea has been shown to block tracheal-specific melanization ([@bib54]). To determine whether tracheal blackening in *dPTPMT1 RNAi* larvae was a result of tracheal-specific melanization being activated, we knocked down *MP1* in the trachea by *btl-GAL4*. Tracheal-specific *MP1* RNAi did not reduce tracheal blackening; however, it did partially rescue viability ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F), suggesting that MP1 mediates tracheal blackening through other tissues in *dPTPMT1 RNAi*.

Data from Flybase ([www.flybase.org](http://www.flybase.org){#intref0010}) show that *dPTPMT1* is ubiquitously expressed. To determine whether dPTPMT1 is required in non-tracheal tissues to prevent tracheal blackening, we knocked down *dPTPMT1* using drivers specific to the nervous system (multiple *elav-GAL4* drivers and *ey-GAL4*), the muscles (*Mhc-GAL4* and *C57-GAL4*), and the fat bodies/hemocytes (*Pxn-GAL4*, *Cg-GAL4*). *dPTPMT1* RNAi by these drivers did not result in any apparent lethality, blackening phenotypes, or other visible phenotypes ([Figure S2](#mmc1){ref-type="supplementary-material"}G), suggesting that tracheal epithelial cells are highly sensitive to loss of *dPTPMT1*.

Next, we examined *dPTPMT1* CRISPR mutants and found that third instar escapers from all three CRISPR lines showed substantial tracheal blackening as homozygotes and transheterozygotes ([Figures 2](#fig2){ref-type="fig"}H, 2I, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B). Ubiquitous expression of dPTPMT1 in *dPTPMT1*^*mut1*^ transheterozygotes resulted in no tracheal blackening in rescued adults (n = 4 replicates, 47--58 adults for each repeat). Interestingly, although ubiquitous expression of *hPTPMT1-3*×*FLAG* rescued viability in *dPTPMT1*^*mut1*^ transheterozygotes ([Figure 1](#fig1){ref-type="fig"}C), 20% of these adults showed tracheal blackening (n = 3 replicates, 29--48 adults for each repeat). Importantly, ubiquitous expression of *hPTPMT1* but not *hPTPMT1-CD* also caused tracheal blackening in a wild-type background. Twenty percent of adults with *hPTPMT1* expression showed tracheal blackening compared with 0% of adults with *hPTPMT1-CD* expression (n = 3 replicates, 10 adults for each repeat), suggesting that hPTPMT1 acts as a weak dominant negative for tracheal blackening in *Drosophila*. We were also able to rescue tracheal blackening in *dPTPMT1*^*mut1*^ transheterozygotes with tracheal-specific expression of wild-type *dPTPMT1-3*×*FLAG* but not *CD* or *ΔMTS*-*dPTPMT1-3*×*FLAG* ([Figure 2](#fig2){ref-type="fig"}I). Collectively, these data demonstrate that dPTPMT1 is essential to prevent tracheal blackening in a cell-autonomous manner and this function is dependent upon dPTPMT1\'s mitochondrial localization and phosphatase activity.

dPTPMT1 Depletion Results in *Drosomycin* Expression in the Trachea {#sec2.3}
-------------------------------------------------------------------

Because tracheal melanization has been shown to induce the expression of one of the AMPs, *Drosomycin (Drs)* ([@bib54]), we assayed *dPTPMT1* RNAi and CRISPR mutant larvae for expression of *Drs*. qPCR revealed that *Drs* was significantly upregulated in ubiquitous *dPTPMT1* RNAi adults and in *dPTPMT1*^*mut1*^ homozygous third instar escapers ([Figures 3](#fig3){ref-type="fig"}A and 3B). Ubiquitous *dPTPMT1* RNAi third instars also showed increased *Drs* expression by qPCR, although this increase was not statistically significant ([Figure S3](#mmc1){ref-type="supplementary-material"}C). We next examined localization of *Drs-GFP* expression in adults and third instar larvae with ubiquitous *dPTPMT1* RNAi, using *Drs-GFP* reporter flies ([@bib13]). We saw an increased percentage of both adults and larvae with *Drs-GFP* expression in their trachea ([Figures 3](#fig3){ref-type="fig"}C--3F). We also examined *Drs-GFP* in *white* RNAi trachea, which have a knockdown of the transporter involved in pigmentation of the eye ([@bib30]). We did not see a significant increase in the percentage of *white* RNAi adults with *Drs-GFP* in the trachea ([Figures 3](#fig3){ref-type="fig"}C and 3D), indicating that the lack of dPTPMT1, rather than the RNAi system itself, is responsible for this phenotype.Figure 3dPTPMT1 Depletion Results in *Drs* Expression in the Trachea(A and B) (A) qPCR analysis of *Drs* expression using whole-fly lysates. n = 3--6 replicates of 15--20 0- to 2-day-old adult males (A) or third instars (B). Data are represented as mean ± SEM and ∗∗p \< .01, ∗∗∗p \< 0.001, by one-tailed Student\'s t test.(C) *Drs-GFP* expression in *dPTPMT1* RNAi adult females, 0--2 days old. Arrow points to signal in the leg trachea. Females are heterozygous for *y* mutation (*y/y*^*+*^). Scale bars, 250 μm.(D) Percentage of adult females with *Drs-GFP* in the trachea. Females are heterozygous for *y* mutation (*y/y*^*+*^). n = 3 replicates, 17--57 for each repeat, 0--2 days old. Data are represented as mean ± SEM and ∗∗∗p \< 0.001 by chi-square test.(E) *Drs-GFP* expression in *dPTPMT1* RNAi third instar males. Arrow points to *Drs-GFP* expression in the dorsal trunk of the trachea and posterior spiracles. Dashed box shows a higher magnification image of the affected area. Scale bars, 250 μm.(F) Percentage of third instar males with *Drs-GFP* expression in the trachea. n = 4--7 replicates, 12--53 for each repeat.Data are represented as mean ± SEM and ∗∗∗p \< 0.001 by chi-square test. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Lastly, we asked whether tracheal blackening and *Drs* elevation were specific to the loss of *dPTPMT1*, or a general by-product of mitochondrial dysfunction. To answer this question, we examined larvae lacking *dMIC60*, a key mitochondrial player for maintaining mitochondrial structure and function ([@bib58], [@bib57]). We found that only 2.3% of third instars (n = 86) had tracheal blackening as compared with 46%--100% in *dPTPMT1* mutants and only 7% had tracheal *Drs-GFP* expression (±4% versus *w*^*1118*^ control: 0% ± 0%, n = 2--3 replicates, 10--28 for each repeat) as compared with 59%--90% in *dPTPMT1* mutants. This result suggests that tracheal blackening and *Drs* elevation are unlikely non-specific responses to general mitochondrial dysfunction. Taken together, dPTPMT1 is required to prevent both tracheal blackening and *Drs* upregulation.

dPTPMT1 Depletion Causes Tracheal Air-Filling Defects {#sec2.4}
-----------------------------------------------------

Because we found that tracheal blackening was absent in first instar larvae with tracheal-specific *dPTPMT1* RNAi, but highly penetrant in second instars, we performed an in-depth examination of these larvae during the first-second instar molt. We inspected the trachea of *dPTPMT1* RNAi first instars and discovered that these mutants failed to fill their trachea with air upon completion of molting ([Figures 4](#fig4){ref-type="fig"}A and 4B). Failure of tracheal air filling was only observed in *dPTPMT1* RNAi but not in *GFP* RNAi larvae ([Figures 4](#fig4){ref-type="fig"}A and 4B). First instars with tracheal-specific *dPTPMT1* RNAi examined at hatching (24 h AEL, n = 5, *btl-GAL4 \> UAS-dPTPMT1* RNAi 1, *UAS-mito-GFP*) and just prior to molting (48 h AEL, n = 5, *btl*-*GAL4* \> *UAS*-*dPTPMT1* RNAi 1, *UAS-mito-GFP*) showed no air-filling defects in the trachea, suggesting that these defects occur during or immediately following molting. We examined *dPTPMT1*^*mut1*^ homozygous and transheterozygous third instar escapers and found that they also showed defects in tracheal air filling, although this phenotype was less penetrant, possibly due to genetic backgrounds and the resistance of escapers to stressors ([Figure 4](#fig4){ref-type="fig"}C). In addition, TEM on the trachea of a third instar larva with ubiquitous *dPTPMT1* RNAi and on a larva with tracheal-specific *dPTPMT1* RNAi revealed that the tracheal lumina of these larvae were filled with unidentifiable membranous materials as well as what we presumed to be molting fluid ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2D). Together, these data show that *dPTPMT1* mutants fail to fill their trachea with air and fail to clear fluid from the tracheal lumen.Figure 4dPTPMT1 Depletion Results in Air Filling and Mitochondrial Defects in the Trachea(A) Air-filling defects in second instars with tracheal-specific *dPTPMT1* RNAi. Red arrows indicate trachea. In *dPTPMT1* RNAi a portion of the posterior dorsal trunk shows air filling, but the remainder of the dorsal trunk is unfilled. Trachea filled with air appears darker than the adjacent tissues owing to differences in the refractive indices of liquid and air. Scale bars, 100 μm.(B) Percentage of second instars with air-filling defects with tracheal-specific *dPTPMT1* RNAi. n = 3 replicates, 6--12 for each repeat. Data are represented as mean ± SEM and ∗∗∗p \< 0.001 by chi-square test.(C) Percentage of *dPTPMT1*^*mut1*^ third instars showing tracheal air-filling defects. n = 3--6 replicates, 14--33 for each repeat. Data are represented as mean ± SEM and ∗∗∗p \< 0.001 by chi-square test.(D) Taenidial folds (arrows) in dissected trachea captured by light microscopy show no defects in tracheal-specific *dPTPMT1* RNAi second instars. Note that these mutant tracheae are transparent because of the lack of air. The same results were seen in 8--22 larvae from two independent crosses. Scale bars, 100 μm.(E) Timeline of events in tracheal-specific *dPTPMT1* RNAi larvae undergoing first to second instar molt.(F) Live imaging of mito-GFP within the dorsal trunk of the trachea of first instars at hatching, just prior to molting ("pre-molting"), and newly molted second instars ("post-molting"). The same results were seen in ten larvae from two independent crosses. Scale bars, 5 μm.(G) Quantification of fluorescence ratios of mito-roGFP2-Grx1 expressed in trachea of second instars. n = 32--38 from three independent crosses. Boxes show 25^th^/75^th^ percentiles, whiskers are the minimum and maximum values, and x is the median marker and ∗∗∗p \< 0.001 by one-tailed Student\'s t test.(H) Relative ATP levels, normalized to total protein. n = 7 independent experiments. Five-day-old *Pink11*^*RV*^ (control) and *Pink1*^*B9*^ adult males ([@bib41]) were used as a positive control. Ubiquitous *dPTPMT1* RNAi were adult males (0--2 days old) and *dPTPMT1*^*mut1*^ were third instars. Statistical significance is given relative to respective controls (black bar). Data are represented as mean ± SEM and ∗p \< 0.05, ∗∗∗p \< 0.001 by one-tailed Student\'s t test.(I) Viability of adults with tracheal-specific RNAi of enzymes involved in CL biosynthesis raised at 25°C, 0- to 2-day-old adults. For simplicity only one background control is shown. Genotypic frequency is calculated for the genotype of interest and then normalized to its expected genotypic frequency. Statistical significance is given relative to respective controls. *dPGS1* RNAi viability is significantly increased relative to its control. Data are represented as mean ± SEM and ∗p \< 0.05, ∗∗∗p \< 0.001 by chi-square test.(J) Tracheal blackening and *Drs-GFP* expression in adult females (0--2 days old) with ubiquitous RNAi of CL biosynthesis enzymes. Females are heterozygous for *y* mutation (*y/y*^*+*^). Statistical significance is given relative to *Act5C-GAL4\>white* RNAi. n = 3 replicates, 17--83 for each repeat. Data for *Drs-GFP* for controls and *dPTPMT1* RNAi are the same as in [Figure 3](#fig3){ref-type="fig"}D.Data are represented as mean ± SEM and ∗∗∗p \< 0.001 by chi-square test. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

To exclude the possibility that structural defects were responsible for failed fluid clearance and air filling, we examined the taenidia of second instars and saw no obvious defects in the structure of taenidia in either of our two independent RNAi lines, despite the obvious lack of air in their trachea ([Figure 4](#fig4){ref-type="fig"}D). TEM on third instar larvae with ubiquitous and tracheal-specific *dPTPMT1* RNAi did show some abnormally formed taenidia ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2D). This result suggests that these tracheal phenotypes are not caused by gross cuticular defects; however, subtler defects in taenidial structure may play a role.

To determine the temporal relationship between failure of air filling and tracheal blackening, we performed a time course analysis. We found that failure of air filling was followed by blackening of the trachea, within 30--90 min of molting completion (n = 15--17, 2 independent crosses) ([Figure 4](#fig4){ref-type="fig"}E). Importantly, although we observed nearly complete penetrance of both tracheal blackening and tracheal air filling defects in tracheal-specific *dPTPMT1* RNAi larvae ([Figures 2](#fig2){ref-type="fig"}F and [4](#fig4){ref-type="fig"}B), we found that *dPTPMT1*^*mut1*^ homozygous and transheterozygous third instar escapers showed a higher frequency of tracheal blackening than air-filling defects ([Figures 2](#fig2){ref-type="fig"}I and [4](#fig4){ref-type="fig"}C). These results suggest that, although the failure of tracheal air filling precedes tracheal blackening in tracheal-specific *dPTPMT1* RNAi, the air-filling failure is not absolutely required for blackening. It is likely both phenotypes are a consequence of an initial defect in the trachea due to a lack of dPTPMT1.

dPTPMT1 Depletion Leads to Mitochondrial Aggregates Prior to Failure of Air Filling {#sec2.5}
-----------------------------------------------------------------------------------

We set out to search for any defect that occurred earlier than tracheal air-filling failure and blackening in our mutants. Because dPTPMT1 is a mitochondrially localized phosphatase, we hypothesized that *dPTPMT1* deficiency disrupted mitochondrial function in tracheal epithelial cells, which consequently interfered with air filling during molting. We examined mitochondrial function in first and second instars with tracheal-specific *dPTPMT1* RNAi by *btl-GAL4*, because they showed a strong, penetrant phenotype with a precise onset.

We expressed *UAS-mito-GFP* in tracheal-specific *dPTPMT1* RNAi larvae and live-imaged mito-GFP within the trachea. We found that, although mito-GFP signal appeared normal at hatching, enlarged mito-GFP puncta started to form just prior to molting in first instars and persisted in recently molted second instars ([Figure 4](#fig4){ref-type="fig"}F). At both developmental stages, these puncta were present throughout the dorsal trunk and tracheal branches. Notably, there was a greater number of large mito-GFP puncta in late first instars than in early second instars ([Figure 4](#fig4){ref-type="fig"}F). Importantly, this mitochondrial phenotype preceded the air-filling phenotype ([Figure 4](#fig4){ref-type="fig"}E). To exclude the possibility that these mito-GFP puncta were an artifact of our RNAi system, we examined mito-GFP in the trachea of larvae with tracheal-specific knockdown of *white*. In these larvae, mito-GFP appeared normal, as in controls ([Figure 4](#fig4){ref-type="fig"}F). Large mito-GFP puncta were also present in *dPTPMT1* RNAi trachea using two additional independent mitochondrially localizing GFP lines ([Figure S3](#mmc1){ref-type="supplementary-material"}D). These large, irregular mito-GFP puncta may represent clusters of mitochondria. Indeed, under TEM we saw individual mitochondria with intact crista structure aggregated in a tracheal epithelial cell of a third instar escaper with tracheal-specific *dPTPMT1* RNAi ([Figure S3](#mmc1){ref-type="supplementary-material"}E). To eliminate the possibility that the air-filling failure we observed in *dPTPMT1* mutants was a result of tracheal epithelial cell death, we examined tracheal cells using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. We saw no significant differences in the number of TUNEL-positive cells between mutants and controls ([Figure S3](#mmc1){ref-type="supplementary-material"}F), suggesting that *dPTPMT1*-depleted tracheal epithelial cells are not apoptotic. Collectively, these results suggest that a defect in mitochondria could be the earliest phenotype in *dPTPMT1* mutant trachea ([Figure 4](#fig4){ref-type="fig"}E).

dPTPMT1 Depletion Compromises Mitochondrial ROS Production in the Trachea and ATP Levels {#sec2.6}
----------------------------------------------------------------------------------------

Defective tracheal air filling causes anoxia, which consequently impacts mitochondrial aerobic respiration. We examined mitochondrial reactive oxidative species (ROS), which are a key by-product of mitochondrial oxidative phosphorylation, in tracheal epithelial cells. We used two genetically encoded mitochondrial ROS sensors: *UAS-mito-roGFP2-Grx1*, a reporter of the glutathione redox potential, which indicates general ROS and reactive nitrogenous species (RNS) ([@bib28]), and *UAS-mito-roGFP2-Orp1*, a hydrogen peroxide (H~2~O~2~) sensor ([@bib4]; [@bib6]). roGFPs are redox-sensitive GFPs that react to oxidants and reductants, resulting in ratiometric changes in fluorescence emitted at 500--530 nm when the probe is excited at 405 and 488 nm ([@bib10]; [@bib20]). An increase in the 405/488 nm ratio indicates increased oxidant concentration. Coupling roGFP to Grx1 and Orp1 enhances its specificity for glutathione and H~2~O~2~, respectively ([@bib18], [@bib19]). We did not observe significant differences in the fluorescence ratio (405/488 nm) of the two ROS reporters between controls and tracheal-specific RNAi of *dPTPMT1* by *btl-GAL4* at 24 h AEL (first instars) ([Figures S3](#mmc1){ref-type="supplementary-material"}G and S3H). However, we did see a significant decrease in the fluorescence ratio of *mito*-*roGFP2*-*Grx1* in second instars of *dPTPMT1* RNAi ([Figure 4](#fig4){ref-type="fig"}G). We also detected a decrease in H~2~O~2~ levels as measured by *mito-roGFP2-Orp1* in second instars of *dPTPMT1* RNAi, although this difference was not statistically significant ([Figure S3](#mmc1){ref-type="supplementary-material"}H). These results indicate reduced ROS levels in *dPTPMT1* RNAi. The timing of the occurrence of ROS reduction coincided with the failure of tracheal air filling in *dPTPMT1* RNAi. Both phenotypes were not present in first instars but were present after molting in second instars. It is likely that the lack of air within the trachea reduced mitochondrial oxidative phosphorylation and consequently decreased ROS generation. Consistent with this hypothesis, ubiquitous *dPTPMT1* RNAi adults, *dPTPMT1*^*mut1*^ homozygous, and transheterozygous third instar escapers all showed lowered ATP levels ([Figure 4](#fig4){ref-type="fig"}H). We used *Pink1*^*B9*^ adult males, which have been reported to show decreased ATP levels, to validate our ATP assay ([@bib41]). Taken together, our findings demonstrate that the lack of dPTPMT1 compromises mitochondrial ROS production in the trachea and reduces ATP levels.

Depletion of the CL Pathway Components Does Not Mimic *dPTPMT1* Deficiency {#sec2.7}
--------------------------------------------------------------------------

Next, we set out to explore the underlying molecular mechanism by which *dPTPMT1* deficiency causes tracheal air-filling failure and immune activation. Because we have demonstrated that the catalytic activity of dPTPMT1 is required to prevent tracheal blackening in *dPTPMT1* mutants, we reasoned that dPTPMT1 might act through its known substrates. PTPMT1 has been implicated in CL synthesis in mammals ([Figure S4](#mmc1){ref-type="supplementary-material"}A), acting as a phosphatidylglycerophosphate (PGP) phosphatase ([@bib68]). It has been found that dPTPMT1 dephosphorylates PGP to phosphatidylglycerol (PG) *in vitro* ([@bib55]). Furthermore, expression of *dPTPMT1* in yeast deficient for the PGP phosphatase, GEP4, rescues decreased viability ([@bib55]), suggesting that PTPMT1\'s role as a PGP phosphatase may be conserved in the fly.

To determine whether loss of dPTPMT1 causes tracheal phenotypes via the CL pathway, we examined tracheal phenotypes in mutants lacking additional enzymes involved in CL synthesis. We identified a *Drosophila* homolog (CG7718: dPGS1) of mammalian phosphatidylglycerophosphate synthase 1 (PGS1), which acts upstream of PTPMT1 in CL synthesis ([Figure S4](#mmc1){ref-type="supplementary-material"}A) ([@bib72]). dPGS1 shares 43% identity to the amino acid sequence of human PGS1. We also tested CL synthase (CG4774; dCLS) and tafazzin (CG8766; dTaz), which act downstream of PTPMT1 in CL synthesis ([Figure S4](#mmc1){ref-type="supplementary-material"}A) ([@bib65]; [@bib2]; [@bib11]). Using qPCR, we confirmed significant knockdown of *dPGS1*, *dCLS*, and *dTaz* by RNAi ([Figure S4](#mmc1){ref-type="supplementary-material"}B). None of these RNAi lines were lethal when driven by the tracheal-specific driver, *btl-GAL4*, at 25°C or 30°C ([Figures 4](#fig4){ref-type="fig"}I and [S4](#mmc1){ref-type="supplementary-material"}C). Furthermore, none of the surviving adults showed tracheal blackening. We also examined adults with ubiquitous RNAi of *dCLS* and *dTaz* driven by *Act5C-GAL4* and did not see tracheal blackening or expression of *Drs-GFP* in the trachea ([Figures 4](#fig4){ref-type="fig"}J and [S4](#mmc1){ref-type="supplementary-material"}D). Ubiquitous *dPGS1* RNAi was pupal lethal, so we examined third instars and again saw no expression of *Drs-GFP* in the trachea, no tracheal blackening, and no tracheal air-filling defects (n = 51--56 third instar female larvae). We further examined third instars of *dCLS* mutants (*dCLS*^*e01021*^*/dCLS*^*C01874*^) ([@bib56]) and saw no evidence of tracheal blackening (*w*^*1118*^ control: 1% ± 0% versus *dCLS* mutant 0% ± 0%; n = 2--3 replicates, 22--102 third instar larvae for each repeat), consistent with our findings with *dCLS* RNAi. Together, these data suggest that the CL biosynthesis pathway is not responsible for the defects observed in the tracheal system with dPTPMT1 deficiency.

Discussion {#sec3}
==========

In this paper, we have revealed a physiological role of dPTPMT1 in the *Drosophila* tracheal system. Loss of dPTPMT1 causes a sequence of defects in the trachea. In first instar larvae, with tracheal-specific *dPTPMT1* RNAi, we have observed mitochondrial clustering just prior to molting. These defects are followed by a failure to fill the trachea with air upon completion of molting and subsequent blackening of the trachea. We have provided evidence suggesting the hypoxic impacts of tracheal air-filling defects on mitochondria, including compromised mitochondrial ROS production and decreased ATP levels. Immune responses are also activated in these mutants, as demonstrated by MP1-dependent melanization and *Drs* upregulation. Our results show that the lack of dPTPMT1 in tracheal epithelial cells interferes with the ability of epithelial cells to perform air filling and activates immune responses.

To date, the mechanisms of tracheal air filling are poorly defined. Our current understanding suggests that this process involves the removal of liquid from the lumen through active and passive ion transport across epithelial cell membranes and the production of gas in the lumen through the dehydration of bicarbonate ions ([@bib15]). Mitochondria play a key role in maintaining homeostasis of ions and metabolites and generating ATP to power ion exchanges. Mitochondrial metabolism and oxidative phosphorylation require a series of biochemical reactions within the mitochondria. One possibility is that dPTPMT1 depletion causes a defect in a specific biochemical reaction in mitochondria, which subsequently impedes the ability of tracheal epithelial cells to conduct air filling. Interestingly, ablation of the carnitine acylcarnitine translocase, COLT, results in failure of air filling at the time of hatching, likely due to an energy deficiency from impaired fatty-acid oxidation ([@bib37]; [@bib21]). It has been shown that loss of PTPMT1 in mammalian cell models causes decreased mitochondrial respiration, which in some cell types is accompanied by decreased ATP levels ([@bib49]; [@bib68]; [@bib66]; [@bib69]). In our fly models, we have observed reduced mitochondrial ROS production and decreased ATP levels ([Figures 4](#fig4){ref-type="fig"}G and 4H). The impairments in second instars appear to be a consequence of failed tracheal air filling; however, the lack of dPTPMT1 may also affect specific metabolic reactions that cause the mitochondrial aggregation observed in first instars prior to molting. It should be noted that general mitochondrial impairments are unlikely to be responsible for the sensitivity of tracheal epithelial cells to the loss of *dPTPMT1*, as we have not seen substantial tracheal blackening and *Drs-GFP* expression in *dMIC60* mutants ([@bib58], [@bib57]).

Although we speculate that the fluid detected within the lumen of affected tracheal cells is molting fluid, it is also possible that it is hemolymph that has infiltrated into the trachea as a result of disruptions in the integrity of the tracheal epithelium. Abnormal tracheal cell-cell junctions trigger tracheal air-filling failure owing to loss of the tracheal paracellular barrier ([@bib22]). Additionally, deformations in the tracheal cuticle and taenidia have been connected with defects in tracheal air filling ([@bib50]; [@bib47]; [@bib23]; [@bib67]; [@bib45]; [@bib51]). Light microscopy reveals no gross morphological defects in the taenidia of dPTPMT1-depleted trachea ([Figure 4](#fig4){ref-type="fig"}D), whereas TEM images show some abnormally formed taenidia ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2D). However, it is difficult to assess the nature of these abnormalities owing to obliquities in sectioning, and this remains a possible explanation for air-filling failure in dPTPMT1 depletion.

Intriguingly, in mammals, one of PTPMT1\'s enzymatic products, PG, is the second most abundant phospholipid within lung surfactant---a mixture of lipids and proteins that reduces surface tension in the lung and prevents alveolar collapse ([@bib3]). PG is produced in the mitochondria and endoplasmic reticulum ([@bib46]; [@bib3]) and has critical functions in immunity in the lung surfactant ([@bib26]; [@bib34], [@bib35]; [@bib24]). PTPMT1 may act in these organelles to generate PG for surfactant ([@bib55]). Although there is currently no direct evidence that flies produce surfactant in the tracheal lumen ([@bib15]), impairments in surfactant production could explain both the air-filling defects and immune activation demonstrated in *dPTPMT1* mutants. However, in our study, RNAi knockdown of *dPGS1*, which acts upstream of dPTPMT1 in the synthesis of PG, does not phenocopy *dPTPMT1* RNAi, suggesting that reduction of PG synthesis is not the reason for the activation of immune responses in mutant flies.

In addition to air-filling defects, we have observed blackening of the trachea following *dPTPMT1* RNAi. Tracheal blackening in ubiquitous *dPTPMT1* RNAi adults is partially blocked by knockdown of *MP1*, a known activator of PPO, which catalyzes melanization ([@bib53], [@bib54]). Interestingly, tracheal-specific knockdown of *MP1* does not block tracheal blackening in *dPTPMT1* RNAi larvae, suggesting that melanization of the trachea is not cell autonomous but instead likely the result of melanization being activated by the hemolymph. Alternatively, this result could indicate that MP1 plays a dispensable role in the activation of tracheal-specific melanization, consistent with recent reports of its more redundant role in systemic immunity ([@bib12]).

Notably, tracheal blackening occurs after the failure of gas filling in tracheal-specific *dPTPMT1* RNAi second instars. Tracheal blackening following failure of tracheal air filling has been reported elsewhere, although the mechanistic basis for this effect has not be elucidated ([@bib14]; [@bib64]). Although in our study tracheal epithelial cells show no evidence of apoptosis ([Figure S3](#mmc1){ref-type="supplementary-material"}F), the possibility remains that these cells are undergoing necrosis, either prior to the occurrence of air-filling defects or following these defects as a result of hypoxia. Importantly, necrotic cells have been shown to activate innate immune pathways, including melanization and AMP expression, likely through damage-associated molecular patterns (DAMPs) ([@bib8]; [@bib27]; [@bib36]; [@bib48]). Hypoxia may also directly activate immune responses ([@bib1]; [@bib5]). Flies grown in hypoxic conditions have been reported to activate AMP expression in the trachea, including *Drs* ([@bib1]). Additionally, mitochondrial stress has been shown to lead to the release of mitochondrial DAMPs and the activation of innate immune responses ([@bib31]; [@bib70]; [@bib44]; [@bib62]; [@bib61]). These are a few explanations for the melanization and *Drs* elevation observed in the trachea, although our current study does not rule out a role for pathogens in the induction of these immune responses.

Our work using a *Drosophila* model of dPTPMT1 depletion adds to our understanding of the importance of dPTPMT1 in sustaining cellular and organismal functions. Mitochondrial activities mediated by dPTPMT1 likely determine the ability of tracheal epithelial cells to support air filling, which in turn enables mitochondrial oxidative phosphorylation and all essential cellular activities. Our *dPTPMT1* mutants and transgenes generated here will provide a useful toolkit to dissect the tissue-specific functions of dPTPMT1 and may help us elucidate additional roles for this phosphatase in mitochondrial biology.

Limitations of the Study {#sec3.1}
------------------------

As mentioned in the text, tracheal sectioning for TEM was performed transversely, and thus obliquity in the sections limits our ability to make conclusions about defects in the taenidial ultrastructure. Although we described a number of tracheal phenotypes resulting from dPTPMT1 deficiency, the molecular mechanisms responsible for their manifestations remain undefined.
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All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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